Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lawrence Einhorn, M.D.
Hoosier Oncology Group, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- Medical Consultants, P.C.
Muncie, Indiana, United States
- Siteman Cancer Center
St Louis, Missouri, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Froedtert/medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2007
- Primary completion
- 31 Dec 2010
- Completion
- 28 Feb 2011
- Last update posted
- 6 Apr 2016
- Registered enrollment
- 69
- Registry id
- NCT00572572
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.